Avrobio Shares Rise 12% After ILAP Designation in U.K. for AVR-RD-02 Gene Therapy
marketwatch.com
news
2022-10-18 16:28:00

By Chris Wack Avrobio Inc. shares were up 12% to 68 cents after the company said the U.K. Medicines and Healthcare products Regulatory Agency has granted an innovation passport under the Innovative Licensing and Access Pathway to investigational AVR-RD-02. AVR-RD-02 is a first-in-class gene therapy that uses patients' own hematopoietic stem cells to treat Gaucher disease, a rare lysosomal disorder that can lead to multiorgan pathology, clinical morbidity and early mortality. The innovation passport is the first step in the ILAP process, triggering the MHRA and its partner agencies to chart a road map for regulatory and development milestones with the goal of early patient access in the U.
